Bavarian Nordic May Seek Government Funding for Anthrax Vaccine

Bavarian Nordic A/S, the Danish company that’s developing a prostate-cancer treatment, may seek government funding to help develop its anthrax vaccine, said Chief Executive Officer Anders Hedegaard.

Bavarian Nordic, based in Kvistgaard, may ask governments, starting with the U.S., to fund its MVA-BN anthrax vaccine should pre-clinical data justify further testing, Hedegaard said in an interview at a conference in Stockholm today.